Realistically, many users undergo sessions weekly or monthly
Can You Keep the Weight Off
Route of administration and lifestyle fit For patients, the biggest differences lie in how these medications fit into their current lifestyle and life stage: Oral GLP1s require daily dosing Injectables are once weekly but require needles Roughly one in four adults has needle aversion, and oral options may open the door for patients previously unwilling or unable to use injectables
Avoid added sugars : Many creatine products contain dextrose or other simple carbohydrates
pharmaphorum news pharmaphorum news 3,490 followers More articles by pharmaphorum Jul 24, 2026 Re-rostered FDA committee backs peptide compounding - NEWS - 24.07.26 This Friday, the recently revamped FDA Pharmacy Compounding Advisory Committee has narrowly voted in favour of Jul 23, 2026 EU clears AZ's SERD camizestrant, as FDA review drags on - NEWS - 23.07.26 This Thursday, AstraZeneca's new breast cancer therapy Etcamah has claimed landmark frontline approval for use in the Jul 22, 2026 Trump announces 100% tariff on generics imports - NEWS - 22.07.26 The Trump Administration's pharmaceutical tariffs are back with a new target: generic medicines, which will see a 100% Jul 21, 2026 New UK PM shuts down science and tech department - NEWS - 21.07.26 This Tuesday, the UK's new Prime Minister Andy Burnham has abolished the Department for Science, Innovation and Jul 20, 2026 Novo's Wegovy pill cleared for weight loss in EU - TOP STORIES - 20.07.26 In this weeks Top Stories, the EU approved Novo Nordisk's pill formulation of weight-loss therapy Wegovy, keeping the Jul 17, 2026 MSD gets first FDA okay for oral PCSK9 cholesterol drug - NEWS - 17.07.26 This Friday, MSD has claimed a first in cardiovascular medicine after winning FDA approval for Lipfendra, the first Jul 16, 2026 Novo's Wegovy pill cleared for weight loss in EU - NEWS - 16.07.26 This Thursday, Novo Nordisk has secured European approval for its Wegovy pill, making it the first oral GLP-1 agonist Jul 15, 2026 Celcuity gets FDA nod for first-in-class breast cancer drug - NEWS - 15.07.26 This Wednesday, Celcuity has won FDA approval for gedatolisib its first product as a treatment for patients with a Jul 14, 2026 AstraZeneca adds another Chinese asset, from Dizal - NEWS - 14.07.26 This Tuesday, AstraZeneca has continued its dealmaking spree in China, signing a $1.5 billion agreement with Dizal Jul 13, 2026 Major trial launched to explore GLP-1 benefit in dementia - NEWS - 13.07.26 This Monday, a $100m trial has been launched to see if lifestyle changes coupled with GLP-1 agonists or similar Explore content categories
Retatrutide is thought to promote weight loss by increasing energy expenditure as well as decreasing energy consumption
